BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 24, 2024
See today's BioWorld
Home
» Mylan registers first drug labeled as a biosimilar in the Colombian market
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Mylan registers first drug labeled as a biosimilar in the Colombian market
Sep. 18, 2019
By
Sergio Held
No Comments
BOGOTA, Colombia – Mylan NV's Ogivri (trastuzumab) has become the first registered biosimilar in Colombia, to be marketed by Strenuus Marketing, a Bogota-based drug distributor.
BioWorld
